
Ritonavir
CAS No. 155213-67-5
Ritonavir( A-84538 | ABT-538 )
Catalog No. M12207 CAS No. 155213-67-5
A potent HIV protease inhibitor for treatment of HIV-1 infection.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 28 | In Stock |
![]() ![]() |
10MG | 41 | In Stock |
![]() ![]() |
25MG | 65 | In Stock |
![]() ![]() |
50MG | 93 | In Stock |
![]() ![]() |
100MG | 133 | In Stock |
![]() ![]() |
200MG | 192 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameRitonavir
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent HIV protease inhibitor for treatment of HIV-1 infection.
-
DescriptionA potent HIV protease inhibitor for treatment of HIV-1 infection; also inhibits cytochrome P450-3A4 (CYP3A4).HIV Infection Approved(In Vitro):Ritonavir (ABT 538) is an inhibitor of CYP3A4 mediated testosterone 6β-hydroxylation with mean Ki of 19 nM and also inhibits tolbutamide hydroxylation with IC50 of 4.2 μM. Ritonavir (ABT 538) is found to be a potent inhibitor of CYP3A-mediated biotransformations (nifedipine oxidation with IC50 of 0.07 mM, 17alpha-ethynylestradiol 2-hydroxylation with IC50 of 2 mM; terfenadine hydroxylation with IC50 of 0.14 mM). Ritonavir is also an inhibitor of the reactions mediated by CYP2D6 (IC50=2.5 mM) and CYP2C9/10 (IC50=8.0 mM). Ritonavir results in an increase in cell viability in uninfected human PBMC cultures. Ritonavir markedly decreases the susceptibility of PBMCs to apoptosis correlated with lower levels of caspase-1 expression, decreases in annexin V staining, and reduces caspase-3 activity in uninfected human PBMC cultures. Ritonavir inhibits induction of tumor necrosis factor (TNF) production by PBMCs and monocytes in a time- and dose-dependent manner at nontoxic concentrations. Ritonavir inhibits p-glycoprotein-mediated extrusion of saquinavir with an IC50 of 0.2 μM, indicating a high affinity of ritonavir for p-glycoprotein. Ritonavir inhibits human liver microsomal metabolism of ABT-378 potently with Ki of 13 nM. Ritonavir combined with ABT-378 (at 3:1 and 29:1 ratios) inhibits CYP3A (IC50=1.1 and 4.6 μM), albeit less potently than Ritonavir (IC50=0.14 μM).
-
In Vitro——
-
In Vivo——
-
SynonymsA-84538 | ABT-538
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIVProtease
-
Research AreaInfection
-
IndicationHIV Infection
Chemical Information
-
CAS Number155213-67-5
-
Formula Weight720.9442
-
Molecular FormulaC37H48N6O5S2
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO; H2O:< 0.1 mg/mL
-
SMILESCC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O
-
Chemical Name2,7,10,12-Tetraazatridecanoic acid, 4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-, 5-thiazolylmethyl ester, (3S,4S,6S,9S)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference



-
Apelin-36 (rat, mous...
Endogenous APJ receptor agonist that is secreted by adipocytes. Binds with high affinity to APJ receptors (IC50 = 5.4 nM) and potently inhibits cAMP production in vitro (EC50 = 0.52 nM). Involved in regulation of cardiovascular function, fluid homeostasis and feeding. Blocks entry of some HIV-1 and HIV-2 strains into NP-2/CD4 cells expressing APJ.
-
Elvitegravir
Elvitegravir (GS-9137, JTK-303) is an HIV integrase inhibitor for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively.
-
KM-023
KM-023 is a new second-generation non-nucleoside reverse transcriptase inhibitor for the study of human immunodeficiency virus (HIV) type 1 infection.